Herbal drug for treatment of Irritable bowel syndrome (IBS)

Efficacy of herbal drug that is composed of essential oil of Zataria multiflora Boiss, Trachyspermum ammi and Anethum graveolens L, in treatment of Irritable bowel syndrome (IBS).

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016072629026N3

Enrollment

Registered

2016-12-29

Start date

2016-07-05

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome. Irritable bowel syndrome

Interventions

Intervention 1: ntervention group: Prescription of edible capsule containing 180mg of essential oil of Ajwain fruit, Zataria Multifora and Dill oil, 2 times a day for 2 weeks. Intervention 2: Control

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Written consent and complete knowledge about the study. Being diagnosed with Irritable bowel syndrome based on the ROME III criteria.

Exclusion criteria

Exclusion criteria: The participants’ lack of consent to continue their participation in the study. Kidney and liver diseases based on laboratory tests. Warning symptoms of gastric and intestinal cancers, other chronic digestive diseases and peptic ulcer disease based on patient history, physical examination and medical records.

Design outcomes

Primary

Measure	Time frame
Quality of life. Timepoint: Before intervention, end of intervention and 2 weeks after intervention. Method of measurement: IBS Quality of life(IBS-QOL).;Relife of symptoms. Timepoint: End of intervention and 2 weeks after intervention. Method of measurement: IBS Adequate relief (IBS-AR).;Relife of symptoms. Timepoint: End of intervention and 2 weeks after intervention. Method of measurement: IBS Global Assessment improvement(IBS-GAI).;Average score of IBS Symptom Severity Scale(IBS-SSS). Timepoint: Before intervention, end of intervention and 2 weeks after intervention. Method of measurement: IBS Symptom Severity Scale(IBS-SSS).	—

Measure

Time frame

Quality of life. Timepoint: Before intervention, end of intervention and 2 weeks after intervention. Method of measurement: IBS Quality of life(IBS-QOL).;Relife of symptoms. Timepoint: End of intervention and 2 weeks after intervention. Method of measurement: IBS Adequate relief (IBS-AR).;Relife of symptoms. Timepoint: End of intervention and 2 weeks after intervention. Method of measurement: IBS Global Assessment improvement(IBS-GAI).;Average score of IBS Symptom Severity Scale(IBS-SSS). Timepoint: Before intervention, end of intervention and 2 weeks after intervention. Method of measurement: IBS Symptom Severity Scale(IBS-SSS).

—

Secondary

Measure	Time frame
Amount of drug consumption. Timepoint: After intervention. Method of measurement: By checking the residual amount of drug after intervention.;Liver enzymes disorder. Timepoint: Before and after intervention. Method of measurement: Labratory test(AST,ALT,ALP,Billi T,D).;Renal dysfunction. Timepoint: Before and after intervention. Method of measurement: Labratory test(BUN,Cr).;Drug side effects. Timepoint: During and after intervention. Method of measurement: Entry the side effects by patient and clinical caregiver in side effects form.	—

Measure

Time frame

Amount of drug consumption. Timepoint: After intervention. Method of measurement: By checking the residual amount of drug after intervention.;Liver enzymes disorder. Timepoint: Before and after intervention. Method of measurement: Labratory test(AST,ALT,ALP,Billi T,D).;Renal dysfunction. Timepoint: Before and after intervention. Method of measurement: Labratory test(BUN,Cr).;Drug side effects. Timepoint: During and after intervention. Method of measurement: Entry the side effects by patient and clinical caregiver in side effects form.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGhasem Bordbar

Hormozgan University of Medical Science

ghasem.bordbar@hums.ac.ir+98 76 3333 7192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026